Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients

Alice Vajda, Laure Marignol, Ruth Foley, Thomas H Lynch, Mark Lawler, Donal Hollywood, Mark Lawler

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Despite the advances in prostate cancer diagnosis and treatment, current therapies are not curative in a significant proportion of patients. Gene-directed enzyme prodrug therapy (GDEPT), when combined with radiation therapy, could improve the outcome of treatment for prostate cancer, the second leading cause of cancer death in the western world. GDEPT involves the introduction of a therapeutic transgene, which can be targeted to the tumour cells. A prodrug is administered systemically and is converted to its toxic form only in those cells containing the transgene, resulting in cell kill. This review will discuss the clinical trials which have investigated the potential of GDEPT at various stages of prostate cancer progression. The advantages of using GDEPT in combination with radiotherapy will be examined, as well as some of the recent advances which enhance the potential utility of GDEPT.

Original languageEnglish
Pages (from-to)643-54
Number of pages12
JournalCancer treatment reviews
Volume37
Issue number8
DOIs
Publication statusPublished - Dec 2011

Bibliographical note

Copyright © 2011 Elsevier Ltd. All rights reserved.

Keywords

  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Enzyme Therapy
  • Genetic Therapy
  • Genetic Vectors
  • Humans
  • Male
  • Prodrugs
  • Prostatic Neoplasms
  • Radiation-Sensitizing Agents
  • Radiotherapy

Fingerprint Dive into the research topics of 'Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients'. Together they form a unique fingerprint.

  • Cite this